# CKD-330 Drug-Drug Interaction Study (Candesartan)

> **NCT02064621** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 24 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Candesartan 32mg
- **DRUG:** Candesartan 32mg/Amlodipine 10mg

## Key facts

- **NCT ID:** NCT02064621
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02064621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02064621, "CKD-330 Drug-Drug Interaction Study (Candesartan)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02064621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*